Результати пошуку

з
 
  


п/п
Номер
патенту
Назва винаходу та фрагмент реферату Дата публікації патента
1 AP9200445D0
NEW SUBSTITUTED PYRAZOLYLPYRAZOLES PROCESS FOR THEIR PREPARATION,AS WELL AS INTERMEDIATES,AND THEIR USE AS HERBICIDES

The invention relates to new pyrazolylpyrazoles of general formula I in which R<1>, R<2>, R<3>, R<4> and R<5> have the meanings given in the description, processes for their preparation as well as intermediates, and their use as herbicides.

31.01.1993
2 AP9200461D0
MEDICAMENTS

Formulation comprises a particulate medicament (I) e.g. salmeterol, salbutamol, fluticasone propionate, becolomethasone dipropionate and a fluorocarbon or hydrogen-contg chlorofluorocarbon propellant. Also claimed are the prepn of the surface-modified medicament and a canister for delivering metered doses of the aerosol formulation. Pref., (I) is salmeterol xinafoate (Ia); salbutamol sulphate; flu...

31.01.1993
3 IL102789D0
FLAME-RETARDED,HIGH-IMPACT-STRENGTH STYRENE POLYMER FORMULATIONS

The impact strength of articles made from a flame-retarded formulated HIPS or ABS resin containing an impact modifier is increased by preparing the articles from a formulation obtained by forming a concentrate or masterbatch containing the flame retardant and impact modifier and blending the concentrate with HIPS or ABS resin.

31.01.1993
4 IL88841A
PERMANENT ANTISTATIC-FILMS MADE OF ACID COPOLYMER/ QUATERNARY AMINE MIXTURES

An acid copolymer/quaternary amine mixture is disclosed which is permanently antistatic. The acid copolymer is a copolymer of (i) a major amount by mol % of an alpha-olefin of the formula RCH=CH2 wherein R is H or C1 to C8 alkyl, and (ii) a minor amount by mol % of an alpha,beta-ethylenically unsaturated carboxylic acid. The quaternary amine is of the formula [(R<1>)(R<2>)(R<3>)(R<4>)N]<+> [X]<-> ...

31.01.1993
5 CA2074774A1
METHOD AND DEVICE FOR THE PREPARATION OF SILICONE ELASTOMER FOAM;APPAREIL ET METHODE D'OBTENTION D'UNE MOUSSE ELASTOMERIQUE DE SILICONE

In accordance with the present method for preparing an elastomeric silicone foam, an inert gas is injected under superatmospheric pressure during or after the merging of a silanol-containing organopolysiloxane that is liquid at room temperature an organohydrogenpolysiloxane that is liquid at room temperature, and hydrosilation catalyst, the merging step is followed by mechanical mixing in an enclo...

31.01.1993
6 IL103000D0
SCINTILLATION CAMERA APPARATUS AND METHOD OF PROCESSING IMAGES OBTAINED THEREBY

Data from a nuclear medicine study is classified in real time into categories which include image data relating to image pixels which are essential covarient. The results of the classification process permit a determination of, e.g., whether the camera is properly positioned at an early stage of the study and long before the study is completed. It is then possible to reposition the camera so as to...

31.01.1993
7 OA9559A
1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES.

(-)-Cis-4-amino-1- (2-hydroxymethyl-1,3 -oxathiolan-5-yl)-(1H)- pyrimidin-2-one (I) and its derivs. are new. (I) contg. max. 5 wt% of (+)-enantiomer (pref. below 1 wt%) is also claimed. (I) is prepd. by sepn. from a racemic mixt., preferably by chiral HPLC. The stationary phase used is preferably beta-cyclodextrin or cellulose triacetate. Alternatively sepn. is by enzyme-mediated enantioselective ...

31.01.1993
8 IL102988D0
COMPOSITION CONTAINING A MATRIX MATERIAL FOR THE TREATMENT OF BONE DEFECTS

Kits and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. A matrix having pores large enough to allow cells to populate the matrix and to form blood vessels is used to fill the defect in bone. The matrix filling the bone defect contains an angiogenic factor and also contains an osteogenic ...

31.01.1993
9 IL102967D0
METHOD AND APPARATUS FOR PROGRAMMABLE MEMORY CONTROL WITH ERROR REGULATION AND TEST FUNCTIONS

An electronic circuit (10) for controlling and testing up to eight banks (12) of RAMs (141 - 14n) includes a controller portion (20) for controlling accessing of the RAM banks to permit read and write operations to be carried out, and for initiating testing of the RAMs as well. The circuit (10) also includes a data path portion (22) for detecting parity errors in the data written to and read from ...

31.01.1993
10 CA2074967A1
HEXAPEPTIDE

A hexapeptide represented by formula (II): A-B-Pro-C-D-E ... (I) where A represents an L- or D- form of arginine or lysine whose N-terminal amino group is alkylated or acylated, B represents an L- or D- form of argine, lysine, or histidine, Pro represents an L- or D- form of proline, C represents an L- or D- form of tyrosine, tryptophan, or phenylalanine, D represents an L- or Dform of valine, iso...

31.01.1993
11 CA2075031A1
CONTAINER LINER SYSTEM FOR BULK TRANSFER;SYSTEME DE DOUBLURE DE CONTENEUR DESTINE A LA MANUTENTION DEPRODUIT EN VRAC

CONTAINER LINER SYSTEM FOR BULK TRANSFER This invention relates to systems of handling flowable cargo in lined cargo containers. An inflatable, self-installing liner configured to line the container, when inflated, is installed and inflated within the container. A transparent, rigid bulkhead keeps the filled liner from transferring load directly to access doors to the container. Special inflatable...

31.01.1993
12 OA9547A
STABILIZED THIOCARBONATE SOLUTIONS AND THE USE THEREOF FOR CONTROLLING SOIL PESTS

Aqueous thiocarbonate solutions are stabilized by the addition of base, sulfide and/or polysulfide and the stability and safety of the more concentrated solutions containing 1 weight percent or more equivalent CS2 as a thiocarbonate are achieved as reflected by significant reduction of CS2 partial pressure in such solutions. Such stabilized thiocarbonate solutions are useful for the control of pes...

31.01.1993
13 OA9553A
ANTIVIRAL COMPOUNDS

Compounds of formula I or a pharmaceutically acceptable salt thereof : I R1XArO @(OR2)(OR3), in which formula R1 represents an aliphatic hydrocarbyl group; Ar represents a substituted or unsubstituted aromatic nucleus; X represents -SO2- or -CO- and R2 and R3 which may be identical or different represent moieties of formula (a), (b), (c), (d), (e), (f), (g), (h) or (i): wherein B repre...

31.01.1993
14 IL85118A
NON-NATURAL 3) AND/OR 3*-DEMETHYLAVERMECTINS, ANTIPARASITIC COMPOSITIONS CONTAINING THEM AND METHODS OF COMBATING PARASITES WITH THEM

Non-natural demethylavermectins useful as parasiticides and process therefor.

31.01.1993
15 IL86150A
3,4-DIDEOXY-D- HEXOPYRANOSIDE- NITROSOUREA DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

New 4-deoxysugar nitrosoureas corresponding to the following formula in the form of either the alpha or the beta anomer, in which - R1 denotes especially an alkyl group containing 1 to 12 carbon atoms, - R4 denotes especially H, - R6 denotes especially OH, - Nu denotes the group -(C:O)-N(-NO)-CH2CH2Hal', Hal' denoting especially chlorine. These compounds can be used for the prepara...

31.01.1993
16 IL87290A
EPIPODOPHYLLOTOXIN GLUCOSIDE 4)-PHOSPHATE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Phosphorus-contg. derivs. of 4'-demethyl epipodophyllotoxin glucosides of formula (I) and pharmaceutically acceptable salts are new, where R1 and R6 together complete a 5-6C cycloalkyl gp.; or R1, R6 = 1-8C alkyl; or R6 = H; and R1 = 1-10C alkyl, 2-10C alkenyl, 5-6C cycloalkyl, 2-furyl, 2-thienyl, 6-10C aryl, 7-14C aralkyl or 8-14C aralkanyl, where the aromatic rings are opt. substd. by halogen, 1...

31.01.1993
17 IL87936A
POLYSULFURIC ACID ESTERS OF BIS-ALDONAMIDES AND THEIR DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The aldonic acids on which the esters are based can be linked glycosidically in position 3, 4 or 6 to a galactopyranosyl, mannopyranosyl, glucopyranosyl or oligopyranosyl radical. The compounds have therapeutic activity.

31.01.1993
18 IL102758D0
GLYCOSAMINOGLYCANOID DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The invention relates to a sulfated glycosaminoglycanoid derivative or a pharmaceutically acceptable salt thereof, of which the functional N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, O-sulfate, or OALK(OALK)nOX groups (wherein ALK is an aliphatic hydrocarbon group, n is 0-5, and X is an alkyl or aryl group), provided that at least two functional groups are ...

31.01.1993
19 IL102976D0
BROMIDE SEPARATION AND CONCENTRATION USING SEMIPERMEABLE MEMBRANES

Aqueous solutions containing bromide and one or more polyvalent anions are separated by nanofiltration into two streams, a brine enriched in the bromide and a brine enriched in the polyvalent anion. The bromide-enriched brine can be concentrated using reverse osmosis, and the concentrated brine can be used, e.g., as feed to a process for recovering elemental bromine or for the production of metal ...

31.01.1993
20 IL86958A
HUMAN MONOCLONAL ANTIBODY IGM 16-88, CELL LINES PRODUCING IT AND ANTIGEN RECOGNIZED THEREBY

The present invention comprises the epitope recognized by the human monoclonal antibody 16-88, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring...

31.01.1993